KRAS and pancreatic neoplasm: A549 NSCLC and MiaPaCa-2 pancreatic cancer cells expressing significant KRAS-driven NQO1 levels were hyper-sensitive to treatment with the PARPi rucaparib + KP372-1, but this sensitivity disappeared when the cancer cells were treated with the NQO1 inhibitor DIC (Figures 1F, G).